This phase 2 study investigated ramucirumab in combination with first–line pemetrexed and platinum chemotherapy in advanced/metastatic NSCLC.
READ FULL ARTICLE
From Mdlinx
Ramucirumab Plus Pemetrexed and Platinum Chemotherapy Shows Clinical Activity in Advanced Nonsquamous NSCLC
the Cancer Therapy Advisor take:
According to a new study published in the journal Cancer, researchers have found that ramucirumab demonstrated clinical activity in combination with pemetrexed plus carboplatin or cisplatin in patients with nonsquamous non-small cell lung cancer (NSCLC).
For the open-label, phase 2 study, researchers enrolled 140 patients with stage 4 nonsquamous NSCLC who had not received prior chemotherapy for metastatic disease.
Researchers randomly assigned participants to receive pemetrexed plus carboplatin or cisplatin with or without ramucirumab 10mg/kg once every 3 weeks for four to six cycles, followed by a maintenance phase with pemetrexed with or without ramucirumab.
Results showed a median progression-free survival of 5.6 months for patients who received pemetrexed plus platinum versus 7.2 months for those who received pemetrexed, platinum, and ramucirumab (HR = 0.75; P = 0.132). Patients in the pemetrexed-platinum arm had a objective response rate of 38.0% compared with 49.3% in the ramucirumab arm (P = 0.180).
The disease control rate was 70.4% and 85.5% for the pemetrexed-platinum and ramucirumab arms, respectively (P = 0.032). The most common grade 3 or higher adverse effects were anemia, back pain, fatigue, hypertension, neutropenia, and thrombocytopenia. Ultimately, the primary endpoint of progression-free survival was not met.
